AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...

Patients saw an average 14.5% relative improvement in disease-free survival when compared with the placebo arm of the study after 54 months. Credit: shutterstock / Peakstock Candel Therapeutics’s ...

Cardiff Oncology’s stock price jumped 50% following the Phase II data. Credit: aslysun / Shutterstock. US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial ...

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

A clinical benefit rate of 62.5% was noted among subjects with both mutant and wild-type oestrogen receptor alpha gene disease. Credit: Andrei_R/Shutterstock. Arvinas and Pfizer have shared ...

The UK is seeing an overall improvement in its desirability as a clinical trials location, but it still has ground to make up.

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.